IMV Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.002
- Today's High:
- $0.0811
- Open Price:
- $0.002
- 52W Low:
- $0.03
- 52W High:
- $7.5
- Prev. Close:
- $0.0811
- Volume:
- 8635
Company Statistics
- Market Cap.:
- $9.81 million
- Book Value:
- -0.691
- Revenue TTM:
- $329000
- Operating Margin TTM:
- -12239.21%
- Gross Profit TTM:
- $-23281000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -61.78%
- Return on Equity TTM:
- -508.58%
Company Profile
IMV Inc. had its IPO on 2018-06-01 under the ticker symbol IMV.
The company operates in the Healthcare sector and Biotechnology industry. IMV Inc. has a staff strength of 63 employees.
Stock update
Shares of IMV Inc. opened at $0 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0 - $0.08, and closed at $0.08.
This is a 0% increase from the previous day's closing price.
A total volume of 8,635 shares were traded at the close of the day’s session.
In the last one week, shares of IMV Inc. have slipped by -1.1%.
IMV Inc.'s Key Ratios
IMV Inc. has a market cap of $9.81 million, indicating a price to book ratio of 8.868 and a price to sales ratio of 1303.5947.
In the last 12-months IMV Inc.’s revenue was $329000 with a gross profit of $-23281000 and an EBITDA of $-39584000. The EBITDA ratio measures IMV Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, IMV Inc.’s operating margin was -12239.21% while its return on assets stood at -61.78% with a return of equity of -508.58%.
In Q4, IMV Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 75%.
IMV Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.55 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IMV Inc.’s profitability.
IMV Inc. stock is trading at a EV to sales ratio of 29450.4965 and a EV to EBITDA ratio of -0.6182. Its price to sales ratio in the trailing 12-months stood at 1303.5947.
IMV Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $31.35 million
- Total Liabilities
- $9.42 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $207000
- Dividend Payout Ratio
- 0%
IMV Inc. ended 2024 with $31.35 million in total assets and $0 in total liabilities. Its intangible assets were valued at $31.35 million while shareholder equity stood at $-6602000.00.
IMV Inc. ended 2024 with $0 in deferred long-term liabilities, $9.42 million in other current liabilities, 158106000.00 in common stock, $-192911000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $21.22 million and cash and short-term investments were $21.22 million. The company’s total short-term debt was $367,000 while long-term debt stood at $27.41 million.
IMV Inc.’s total current assets stands at $27.59 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.93 million compared to accounts payable of $3.19 million and inventory worth $0.
In 2024, IMV Inc.'s operating cash flow was $0 while its capital expenditure stood at $207000.
Comparatively, IMV Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.08
- 52-Week High
- $7.5
- 52-Week Low
- $0.03
- Analyst Target Price
- $33.5
IMV Inc. stock is currently trading at $0.08 per share. It touched a 52-week high of $7.5 and a 52-week low of $7.5. Analysts tracking the stock have a 12-month average target price of $33.5.
Its 50-day moving average was $0.34 and 200-day moving average was $2.05 The short ratio stood at 1.56 indicating a short percent outstanding of 0%.
Around 41.2% of the company’s stock are held by insiders while 2037% are held by institutions.
Frequently Asked Questions About IMV Inc.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.